ORCHARD PARK, N.Y., Sept 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- MINRAD
International, Inc. (Amex: BUF) today announced that it has notified RxElite
Holdings, Inc., a wholly-owned subsidiary of RxElite Inc.
(OTC Bulletin Board: RXEI), that it is transitioning its relationship with
respect to RxElite Holdings, Inc.'s rights to be the exclusive distributor of
certain Minrad International Inc.'s anesthetic products in the United States.
Minrad has decided to move into a non-exclusive distributor arrangement with
RxElite.

"As we discussed in our second quarter conference call on August 14, 2008,
we have had ongoing dialogue with the senior management of RxElite to assess
and determine how to increase our joint penetration of anesthetic products in
the United States market. We believe this action will maximize the expertise
of sales forces of both companies as well as the in-house support capabilities
which RxElite has built to launch sevoflurane in the U.S. human anesthetic
market," said David DiGiacinto, President and Chief Operating Officer.

Kirk Kamsler, Minrad's Senior Vice President, Commercial Development also
commented, "We expect and will work towards ensuring that this ongoing change
in selling strategy for our present and future anesthetics in the U.S. market
will be transparent to both the distribution customers and end users of this
product. Minrad already launched in June a direct selling effort for
sevoflurane and isoflurane into the U.S. veterinary market."

     Contact:     David DiGiacinto, President & Chief Operating Officer
                  ddigiacinto@minrad.com
                  Kirk Kamsler, Senior Vice President, Commercial Development
                  kkamsler@minrad.com
                  Charles R. Trego, Jr., Executive Vice President & Chief
                  Financial Officer
                  ctrego@minrad.com

                  (716) 855-1068
                  http://www.minrad.com

About the Company

MINRAD International, Inc. is an interventional pain management company
with real-time image guidance, anesthesia and analgesia, conscious sedation
product lines. The real-time image guidance products facilitate minimally
invasive surgery especially for pain management and have broad applications in
orthopedics, neurosurgery, and interventional radiology. These devices enable
medical professionals to improve the accuracy of interventional procedures and
reduce radiation exposure. MINRAD International also manufactures and markets
generic inhalation anesthetics for use in connection with human and veterinary
surgical procedures. The company is developing a drug/drug delivery system for
conscious sedation, which, similar to nitrous oxide in dental surgery,
provides a patient with pain relief without loss of consciousness. Additional
information can be found at the company's website, http://www.minrad.com.

The information contained in this news release, other than historical
information, consists of forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements may involve
risks and uncertainties that could cause actual results to differ materially
from those described in such statements. Factors that may cause actual results
to differ materially from those expressed or implied by its forward-looking
statements include, but are not limited to, Minrad International's limited
operating history and business development associated with being a growth
stage company; its dependence on key personnel; its need to attract and retain
technical and managerial personnel; its ability to execute its business
strategy; the intense competition it faces; its ability to protect its
intellectual property and proprietary technologies; its exposure to product
liability claims resulting from the use of its products; general economic and
capital market conditions; financial conditions of its customers and their
perception of its financial condition relative to that of its competitors; as
well as those risks described under the heading "Risk Factors" of Minrad
International's Form 10-KSB/A, filed with the Securities and Exchange
Commission on April 21, 2008. Although Minrad International, Inc. believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove to have
been correct.

SOURCE MINRAD International, Inc.

http://www.minrad.com

Copyright (C) 2008 PR Newswire. All rights reserved